Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  alisertib
Find trials that include:  Any drugs shown
Results 1-23 of 23 for your search:
Start Over
Alisertib and Erlotinib Hydrochloride in Treating Patients With Recurrent Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OER-TH-036, NCI-2011-03306, NCT01471964
Alisertib, Abiraterone Acetate, and Prednisone in Treating Patients with Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13P.128, NCI-2013-00895, 2013-02, NCT01848067
Alisertib in Treating Patients With Unresectable Stage III-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC MEL 1036, NCI-2010-02322, NCT01316692
Alisertib in Treating Patients with Advanced or Metastatic Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091102, NCI-2012-01991, CALGB-A091102, CDR0000737403, NCT01653028
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1210013164, NCI-2014-01689, NCT01799278
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-12106, NCI-2012-02794, 2012C0113, NCT01812005
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C14018, NCI-2014-00808, 2013-003713-18, DRKS00007849, U1111-1154-9805, NCT02038647
Alisertib in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 2014-0497, NCI-2014-02568, X14024, NCT02293005
Alisertib, Cetuximab, and Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 10311, NCI-2012-00172, NCT01540682
Alisertib in Combination with Vorinostat in Treating Patients with Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHI-67, NCI-2012-00715, CDR0000729769, CHNMC-PHI-67, NCI#9091, 9091, NCT01567709
Combining MLN8237 with Nab-Paclitaxel in Patients with Advanced Solid Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201210123, NCI-2012-01611, NCT01677559
Alisertib, Bortezomib, and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S12-02028, NCI-2012-01712, CDR0000740877, P9086, 9086, NCT01695941
Alisertib, Cytarabine, and Idarubicin in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-531, NCI-2013-01106, NCT01779843
Alisertib and Romidepsin in Treating Patients with Relapsed or Refractory B-Cell or T-Cell Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0602, NCI-2013-01272, 9342, NCT01897012
Irinotecan Hydrochloride and Alisertib in Treating Patients with Advanced Solid Tumors or Colorectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#234, NCI-2013-01387, X14013, NCT01923337
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#240, NCI-2013-01388, NCT01924260
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients with Recurrent High Grade Gliomas
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.528, NCI-2014-01344, 2013-12, 3007, NCT02186509
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C14019, NCI-2014-01843, U1111-1155-6072, NCT02214147
Alisertib and Fulvestrant in Treating Patients with Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1231, NCI-2014-01726, NCT02219789
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C14020, NCI-2014-02213, NCT02259010
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC PHIXXXX, NCI-2014-02475, 9824, NCT02319018
A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C28002, NCI-2015-01108, 2014-003340-12, U1111-1159-5831, NCT02327169
Start Over